| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 74, 914-919, Copyright © 1992 by Endocrine Society
ARTICLES |
HJ Karga, JM Alexander, ET Hedley-Whyte, A Klibanski and JL Jameson
Department of Medicine, Massachusetts General General Hospital, Boston 02114.
The cellular basis for pituitary neoplasia is poorly understood. Mutations that activate the ras protooncogenes have been identified in a number of different types of human cancers and potentially represent one of the genetic alterations that occur in pituitary tumors. In this study we examined 19 pituitary tumors for the occurrence of ras mutations. The tumor types included 11 nonfunctioning adenomas, 6 somatotroph adenomas, and 2 prolactinomas. Each of the three ras genes (K-ras, N-ras, and H-ras) was amplified from pituitary tumor DNA using the polymerase chain reaction. Oligonucleotide-specific hybridization was used to screen for mutations that inhibit GTPase activity and cause activation of the ras oncogene. No ras mutations were observed in 18 of the pituitary adenomas. However, a mutation was identified in codon 12 of the H-ras gene (Gly to Val) in a recurrent prolactinoma that was highly invasive and ultimately proved to be fatal. We conclude that ras mutations are uncommon in pituitary adenomas, but may provide a marker for highly invasive tumors.
This article has been cited by other articles:
 |
|
 |
|
  A. Gurlek, N. Karavitaki, O. Ansorge, and J. A H Wass What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics Eur. J. Endocrinol., February 1, 2007; 156(2): 143 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Gillam, M. E. Molitch, G. Lombardi, and A. Colao Advances in the Treatment of Prolactinomas Endocr. Rev., August 1, 2006; 27(5): 485 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Heaney Pituitary tumour pathogenesis. Br. Med. Bull., January 1, 2006; 75-76: 81 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Kaltsas, P. Nomikos, G. Kontogeorgos, M. Buchfelder, and A. B. Grossman Diagnosis and Management of Pituitary Carcinomas J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 3089 - 3099. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lania, G. Mantovani, and A. Spada Genetics of Pituitary Tumors: Focus on G-Protein Mutations Experimental Biology and Medicine, October 1, 2003; 228(9): 1004 - 1017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J W Ironside Best Practice No 172: Pituitary gland pathology J. Clin. Pathol., August 1, 2003; 56(8): 561 - 568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. McCabe, N. J. Gittoes, M. C. Sheppard, and J. A. Franklyn Thyroid Receptor {alpha}1 and {alpha}2 Mutations in Nonfunctioning Pituitary Tumors J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 649 - 653. [Abstract] [Full Text]
|
|
|
|
|
|
X. Zhang, G. A. Horwitz, A. P. Heaney, M. Nakashima, T. R. Prezant, M. D. Bronstein, and S. Melmed Pituitary Tumor Transforming Gene (PTTG) Expression in Pituitary Adenomas J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 761 - 767. [Abstract] [Full Text]
|
|
|
|
 |
|
 X. Zhang, G. A. Horwitz, T. R. Prezant, A. Valentini, M. Nakashima, M. D. Bronstein, and S. Melmed Structure, Expression, and Function of Human Pituitary Tumor-Transforming Gene (PTTG) Mol. Endocrinol., January 1, 1999; 13(1): 156 - 166. [Abstract] [Full Text]
|
|
|
|
|
|
S. L. Asa and S. Ezzat The Cytogenesis and Pathogenesis of Pituitary Adenomas Endocr. Rev., December 1, 1998; 19(6): 798 - 827. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. Wynick, C. J. Small, A. Bacon, F. E. Holmes, M. Norman, C. J. Ormandy, E. Kilic, N. C. H. Kerr, M. Ghatei, F. Talamantes, et al. Galanin regulates prolactin release and lactotroph proliferation PNAS, October 13, 1998; 95(21): 12671 - 12676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Daniely, A. Aviram, E. F. Adams, M. Buchfelder, G. Barkai, R. Fahlbusch, B. Goldman, and E. Friedman Comparative Genomic Hybridization Analysis of Nonfunctioning Pituitary Tumors J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1801 - 1805. [Abstract] [Full Text]
|
|
|
|
|
|
S. J. Hurel, P. E. Harris, A. M. McNicol, S. Foster, W. F. Kelly, and P. H. Baylis Metastatic Prolactinoma: Effect of Octreotide, Cabergoline, Carboplatin and Etoposide; Immunocytochemical Analysis of Proto-Oncogene Expression J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 2962 - 2965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Shimon and S. Melmed Pituitary Tumor Pathogenesis J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1675 - 1681. [Full Text] [PDF]
|
|
|
|
|
|
S. A. A. Abbass, S. L. Asa, and S. Ezzat Altered Expression of Fibroblast Growth Factor Receptors in Human Pituitary Adenomas J. Clin. Endocrinol. Metab., April 1, 1997; 82(4): 1160 - 1166. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
